Bora Pharmaceuticals Co Ltd Statistics
Bora Pharmaceuticals Co Ltd (6472) Stock Statistics & Valuation Metrics
Total Valuation
Bora Pharmaceuticals Co Ltd has a market cap or net worth of TWD 51.14B. The enterprise value is TWD 72.16B.
- Market Cap
- TWD 51.14B
- Enterprise Value
- TWD 72.16B
Share Statistics
Bora Pharmaceuticals Co Ltd has 128,019,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 128,019,120
- Owned by Insiders
- ―
- Owned by Institutions
- 3.26%
Financial Efficiency
Bora Pharmaceuticals Co Ltd’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 7.48%.
- Return on Equity (ROE)
- 0.19
- Return on Assets (ROA)
- 0.07
- Return on Invested Capital (ROIC)
- 7.48%
- Return on Capital Employed (ROCE)
- 0.10
- Revenue Per Employee
- 8.43M
- Profits Per Employee
- 1.32M
- Employee Count
- 2,255
- Asset Turnover
- 0.43
- Inventory Turnover
- 3.33
Valuation Ratios
The current PE Ratio of Bora Pharmaceuticals Co Ltd is 32.83. Bora Pharmaceuticals Co Ltd’s PEG ratio is -0.52.
- PE Ratio
- 32.83
- PS Ratio
- 2.63
- PB Ratio
- 3.39
- Price to FCF
- 27.14
- Price to Operating Cash Flow
- 17.10
- PEG Ratio
- -0.52
Income Statement
In the last 12 months, Bora Pharmaceuticals Co Ltd had revenue of 19.01B and earned 2.98B in profits. Earnings per share was 23.90.
- Revenue
- 19.01B
- Gross Profit
- 7.66B
- Operating Income
- 3.29B
- Pretax Income
- 5.28B
- Net Income
- 2.98B
- EBITDA
- 4.23B
- Earnings Per Share (EPS)
- 23.90
Cash Flow
In the last 12 months, operating cash flow was 3.00B and capital expenditures -1.11B, giving a free cash flow of 1.89B billion.
- Operating Cash Flow
- 3.00B
- Free Cash Flow
- 1.89B
- Free Cash Flow per Share
- 14.83
Dividends & Yields
Bora Pharmaceuticals Co Ltd pays an annual dividend of ―, resulting in a dividend yield of 2.50%
- Dividend Per Share
- ―
- Dividend Yield
- 2.50%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.63%
- Earnings Yield
- 2.97%
Stock Price Statistics
- Beta
- 0.17
- 52-Week Price Change
- -37.68%
- 50-Day Moving Average
- 412.13
- 200-Day Moving Average
- 420.05
- Relative Strength Index (RSI)
- 48.73
- Average Volume (3m)
- 816.78K
Important Dates
Bora Pharmaceuticals Co Ltd upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Bora Pharmaceuticals Co Ltd as a current ratio of 1.45, with Debt / Equity ratio of 118.51%
- Current Ratio
- 1.45
- Quick Ratio
- 1.20
- Debt to Market Cap
- 0.29
- Net Debt to EBITDA
- 3.10
- Interest Coverage Ratio
- 6.80
Taxes
In the past 12 months, Bora Pharmaceuticals Co Ltd has paid 829.85M in taxes.
- Income Tax
- 829.85M
- Effective Tax Rate
- 0.16
Enterprise Valuation
Bora Pharmaceuticals Co Ltd EV to EBITDA ratio is 16.06, with an EV/FCF ratio of 34.64.
- EV to Sales
- 3.35
- EV to EBITDA
- 16.06
- EV to Free Cash Flow
- 34.64
- EV to Operating Cash Flow
- 21.82
Balance Sheet
Bora Pharmaceuticals Co Ltd has TWD 8.49B in cash and marketable securities with TWD 21.82B in debt, giving a net cash position of -TWD 13.33B billion.
- Cash & Marketable Securities
- TWD 8.49B
- Total Debt
- TWD 21.82B
- Net Cash
- -TWD 13.33B
- Net Cash Per Share
- -TWD 104.11
- Tangible Book Value Per Share
- TWD 71.34
Margins
Gross margin is 39.06%, with operating margin of 15.41%, and net profit margin of 7.91%.
- Gross Margin
- 39.06%
- Operating Margin
- 15.41%
- Pretax Margin
- 14.01%
- Net Profit Margin
- 7.91%
- EBITDA Margin
- 20.86%
- EBIT Margin
- 15.19%
Analyst Forecast
The average price target for Bora Pharmaceuticals Co Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -5.57%
- EPS Growth Forecast
- -62.77%
